Literature DB >> 11966943

Plasma and urine levels of urinary trypsin inhibitor in patients with acute and fulminant hepatitis.

Shi De Lin1, Ryujin Endo, Akihiro Sato, Yasuhiro Takikawa, Kamon Shirakawa, Kazuyuki Suzuki.   

Abstract

BACKGROUND AND AIM: Urinary trypsin inhibitor (UTI) is synthesized by hepatocytes and excreted into urine. Plasma and urine UTI levels have been measured to evaluate whether these levels may be useful markers in various pathological conditions. However, there has been no study on plasma and urine UTI levels in patients with acute liver diseases. The aim of the present study was to evaluate plasma and urine UTI levels and their relationship with the severity of hepatic damage in patients with acute liver diseases.
METHODS: Plasma and urine UTI levels were measured by newly developed enzyme-linked immunosorbent assay in 15 patients with acute hepatitis (AH), 12 patients with acute severe hepatitis (ASH) and 10 patients with fulminant hepatitis (FH), as assessed on admission. The serial changes in plasma and urine UTI were also observed in some patients with AH and ASH.
RESULTS: Plasma UTI levels (U/mL, median [25-75th percentile]) were: 11.0, (9.5-16.1) in patients with AH; 7.8 (5.6-11.5) in those with ASH; 6.5 (4.0-9.5) in patients with FH; and 9.7 (7.3-11.0) in normal controls. Plasma UTI levels in patients with FH were significantly lower than in those with AH. Plasma UTI levels showed significant positive correlations with the levels of prothrombin time (PT), hepaplastin test, antithrombin III, alpha2-plasmin inhibitor, plasminogen (Plg) and fibrinogen. After the recovery of liver dysfunction, increased plasma UTI levels in patients with AH were decreased, whereas previously decreased plasma UTI levels in patients with ASH were increased. Urine UTI levels were significantly increased in patients with AH compared with those of normal controls. In patients with ASH and FH, urine UTI levels were increased but not significantly. Urine UTI levels significantly positively correlated with PT and Plg. After the recovery of liver dysfunction, previously increased urine UTI levels in patients with AH were decreased. The correlation between plasma UTI and urine UTI levels was not significant.
CONCLUSIONS: The findings of the present study suggested that the levels of plasma and urine UTI changed in patients with AH and were closely related to the abnormalities of coagulo-fibrinolysis, including PT. Further studies are needed to clarify whether these levels may be useful markers to predict the prognosis of acute hepatitis.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 11966943     DOI: 10.1046/j.1440-1746.2002.02676.x

Source DB:  PubMed          Journal:  J Gastroenterol Hepatol        ISSN: 0815-9319            Impact factor:   4.029


  5 in total

Review 1.  Research progress of ulinastatin in the treatment of liver diseases.

Authors:  Shangping Fang; Pengfei Li; Chenxu Zhu; Xiaoxiao Han; Pengju Bao; Wenjun Guo
Journal:  Int J Clin Exp Pathol       Date:  2020-11-01

2.  Protective effects of tumor necrosis factor alpha antibody and ulinastatin on liver ischemic reperfusion in rats.

Authors:  Yan-Ling Yang; Ji-Peng Li; Xiao-Ping Xu; Ke-Feng Dou; Shu-Qiang Yue; Kai-Zong Li
Journal:  World J Gastroenterol       Date:  2004-11-01       Impact factor: 5.742

3.  Urinary trypsin inhibitor reduced neointimal hyperplasia induced by systemic inflammation after balloon injury in rabbits.

Authors:  Junying Kong; Jian Zhang; Lin Li; Guihua Jiang; Xinchun Wang; Xiaojun Liu; Bo Yu
Journal:  Inflamm Res       Date:  2012-10-27       Impact factor: 4.575

4.  Sensitive noninvasive marker for the diagnosis of probable bacterial or viral infection.

Authors:  Saeed A Jortani; Michael J Pugia; Ronald J Elin; Meera Thomas; Edward P Womack; Todd Cast; Roland Valdes
Journal:  J Clin Lab Anal       Date:  2004       Impact factor: 2.352

5.  Levels of Urinary Trypsin Inhibitor and Structure of Its Chondroitin Sulphate Moiety in Type 1 and Type 2 Diabetes.

Authors:  Antonio Junior Lepedda; Gabriele Nieddu; Silvia Rocchiccioli; Nadia Ucciferri; Michela Idini; Pierina De Muro; Marilena Formato
Journal:  J Diabetes Res       Date:  2018-02-06       Impact factor: 4.011

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.